American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

WINDTREE THERAPEUTICS INC /DE/ (WINT)

$0.00 +33.33% OTC: WINT · 15-min delayed

WARRINGTON, Pennsylvania
Public · OTC: WINT

$198.0KRevenue · FY2019

-$1.8MNet income

WINTOTC

About WINDTREE THERAPEUTICS INC /DE/

WINDTREE THERAPEUTICS NEW

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: WINT
Headquarters: WARRINGTON, Pennsylvania
Industry: Pharmaceuticals

Registry IDs

Ticker: WINT OTC
SEC CIK: 946486
EIN: 943171943
SIC: 2836 Biological Products, (No Diagnostic Substances)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Windtree Therapeutics Inc /DE/’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/windtree-therapeutics-inc-de/"><img src="https://americancompanies.com/badge/windtree-therapeutics-inc-de.svg" alt="Windtree Therapeutics Inc /DE/ — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow WINDTREE THERAPEUTICS INC /DE/ and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2019: $198.0K
Net income: -$1.8M
Total assets: $27.9M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: WINT

$0.00 +33.33%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.00 $0.18

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Windtree Therapeutics Inc /DE/ (WINT) Stock Price

Reported a net loss of $1.8M in FY2019.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review WINDTREE THERAPEUTICS INC /DE/.

Write a review

Newsroom

News about WINDTREE THERAPEUTICS INC /DE/

Evofem Revenue Jumps 16 Percent in Q2 The Motley Fool · 2025-08-14 · neutral Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy GlobeNewswire Inc. · 2025-07-24 · positive Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics Benzinga · 2025-03-26 · positive US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert Benzinga · 2025-03-26 · positive Windtree Announces the Addition of Leanne Kelly to Its Board of Directors GlobeNewswire Inc. · 2025-01-13 · positive Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia GlobeNewswire Inc. · 2024-12-09 · positive

News & sentiment via Polygon.io

FAQ

Windtree Therapeutics Inc /DE/: frequently asked questions

Is Windtree Therapeutics Inc /DE/ an American company?

Windtree Therapeutics Inc /DE/ is a US-based company headquartered in Warrington, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Windtree Therapeutics Inc /DE/ headquartered?

Windtree Therapeutics Inc /DE/ is headquartered in Warrington, Pennsylvania, United States.

Is Windtree Therapeutics Inc /DE/ publicly traded?

Yes — Windtree Therapeutics Inc /DE/ is a publicly traded company. Its stock trades under the ticker symbol WINT on the OTC.

What does Windtree Therapeutics Inc /DE/ do?

Windtree Therapeutics Inc /DE/ is an American Pharmaceuticals company in the Health & Beauty sector.

Explore